Ostex to cut workforce and make other savings
This article was originally published in Clinica
Ostex International has cut its workforce by 30% which, together with other cost-cutting measures, is expected to result in a 40% reduction in operating expenses in 1999. The company now believes it has sufficient cash flow for three years of operations, providing it maintains current sales performance.
You may also be interested in...
TTS Pharma CEO Mark Tucker discusses his ambition to bring a legal CBD oil to the UK market, following the recent submission of a European Union novel food application.
Italy Round-Up: Mylan And Polifarma Strike Deal, OTC Market Stable, Cholesterol-Lowering Probiotic Launch
The latest news from Italy's OTC and supplements markets, including the latest sales figures, business deals, product launches, ad regulation and local association activities.
Sandoz CEO Richard Saynor has pledged that the company will ensure stable pricing for essential coronavirus-related medicines amid concerns over how the outbreak will affect the supply chain.